Team:Rutgers/

Welcome
The Rutgers iGEM Team designed two complex genetic circuits, Etch-a-Sketch and Full Adder, and created a software tool, MYS!S. The Etch-a-Sketch circuit enables a lawn of bacteria to be drawn on with a laser. This seemingly inconsequential task presents many engineering challenges: the bacteria need to be sensitive in order to respond to a laser pulse, yet selective to use in ambient lighting. The second circuit allows bacteria to emulate a digital full adder. The circuit makes use of individually non-functional split reporters that can reform functional reporters with the help of fused “zipper” domains. In addition to the circuit, we have made easily fuse-able biobricks of these domains in order to facilitate the engineering of more split proteins, which should assist in the creation of logic circuits. MYS!S aims to improve the parts registry by checking and giving directions to modify Biobricks to conform to assembly standards.
Etch-a-Sketch		Full Adder		Mysis
	The Etch-a-Sketch project aims to create a lawn of bacteria that can be drawn on with a laser pointer. This seemingly inconsequential task actually presents many interesting engineering challenges. In particular, the bacteria need to be extremely sensitive in order to respond to a short light pulse from a laser, but they still must be “selective” enough to use in ambient lighting. We have designed a novel genetic switch that we hope will tackle these problems. If our work proves successful, it will serve as a useful model for future projects that require massive signal amplification. In particular, researchers creating biosensors may find our work very helpful. meow Read More I'll meow upon ready		The Full Adder project seeks to create bacteria that can mimic a digital full adder. Since many teams have difficulty creating even something small like a XOR gate, this project would seem nearly impossible. However, we have found that the problem can be greatly simplified if we use a certain simple “encoding” on the outputs of the full adder. By the end of the summer we hope to demonstrate the world’s first (to our knowledge) bacterial full adder. Our insights may prove useful to any genetic engineer or synthetic biologist working on highly complex systems. If successful, the bacterial full adder may very well become the ancestor to more complicated biological calculators in the future.		A major problem with the current Parts Registry, a library of BioBricks submitted by iGEM teams, is that many parts do not strictly conform to the BioBrick standard which makes certain operations extremely difficult. Rutger's iGEM software team strives to provide a tool to improve the standard parts registry by checking, and if need be modifying, the BioBrick parts. The basic idea is that before a team submits their new BioBrick, it will run the genetic sequences through MYS!S. MYS!S will output the modified genetic sequence, BioCoder source code, and the lab protocol needed to change the unmodified sequence into the modified sequence The long term goal of the project is to further the automation of lab protocols by specifying them through algorithms.

 

 

 

 

G.E.A.R.S., the Genetic Engineering at Rutgers Society, is a group of undergraduates studying engineering and the sciences. Our members have formed the first Rutgers University team to compete in the International Genetically Engineered Machines (iGEM, www.igem.org) competition hosted by the Massachusetts Institute of Technology. This competition is a platform for undergraduates to apply biological and engineering principles learned in the classroom to invent a working biological system with the aim of solving real world problems.

iGEM challenges undergraduates to assemble simple biological parts into complex systems that go beyond those found in nature. These biological parts are known as BioBricks, well-characterized genetic parts that can be combined in the same manner that electrical components are used to assemble new hardware.

Past iGEM team projects have presented novel solutions to medical problems. Projects from past iGEM teams include: a non-infectious bacterium that can bind oxygen and thereby replace red blood cells, bacteria engineered to control mammalian immune cells to treat inflammatory bowel disease, and bacterial fuel cells that can generate an electric current in response to certain chemicals.

Advisors for the Rutgers iGEM team include Dr. Andrew Vershon from the Waksman Institute for Microbiology (Rutgers), Dr. James Stapleton from the Center for Advanced Biotechnology and Medicine (UMDNJ), Dr. Ryan Golhar from The Cancer Institute of New Jersey (UMDNJ), and Dr. Anirvan Sengupta from the BioMaPS Institute for Quantitative Biology (Rutgers).

G.E.A.R.S.,

the Genetic Engineering at Rutgers Society, is a group of undergraduates studying engineering and the sciences. Our members have formed the first Rutgers University team to compete in the International Genetically Engineered Machines (iGEM, www.igem.org) competition hosted by the Massachusetts Institute of Technology. This competition is a platform for undergraduates to apply biological and engineering principles learned in the classroom to invent a working biological system with the aim of solving real world problems.

iGEM challenges undergraduates to assemble simple biological parts into complex systems that go beyond those found in nature. These biological parts are known as BioBricks, well-characterized genetic parts that can be combined in the same manner that electrical components are used to assemble new hardware.

Past iGEM team projects have presented novel solutions to medical problems. Projects from past iGEM teams include: a non-infectious bacterium that can bind oxygen and thereby replace red blood cells, bacteria engineered to control mammalian immune cells to treat inflammatory bowel disease, and bacterial fuel cells that can generate an electric current in response to certain chemicals.

Advisors for the Rutgers iGEM team include Dr. Andrew Vershon from the Waksman Institute for Microbiology (Rutgers), Dr. James Stapleton from the Center for Advanced Biotechnology and Medicine (UMDNJ), Dr. Ryan Golhar from The Cancer Institute of New Jersey (UMDNJ), and Dr. Anirvan Sengupta from the BioMaPS Institute for Quantitative Biology (Rutgers).